EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

15 фев 2023 17:19:50 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

15 фев 2023 02:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

06 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus

09 янв 2023 06:59:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

05 янв 2023 17:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

06 дек 2022 06:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

14 ноя 2022 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

08 ноя 2022 16:16:51 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

01 ноя 2022 16:05:14 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

18 окт 2022 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

26 сен 2022 16:12:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

06 сен 2022 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

10 авг 2022 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2022

01 авг 2022 16:05:47 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022

18 июл 2022 16:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola

07 июл 2022 16:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors

06 июл 2022 16:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

24 июн 2022 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

21 июн 2022 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

02 июн 2022 08:20:49 Источник Nasdaq GlobeNewswire